Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 4/2003

01.09.2003 | New Surgical Horizons

Indications and results of liver transplantation for Echinococcus alveolar infection: an overview

verfasst von: Solange Bresson-Hadni, Stéphane Koch, Jean-Philippe Miguet, Michel Gillet, Georges-André Mantion, Bruno Heyd, Dominique-Angèle Vuitton, a European group of clinicians

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 4/2003

Einloggen, um Zugang zu erhalten

Abstract

Background

Alveolar echinococcosis (AE) of the liver, caused by the larval stage of the fox tapeworm Echinococcus multilocularis, has the characteristics of a slow-growing liver cancer. It is one of the rare parasitic diseases for which a parasitolytic drug is not yet available, and AE is lethal in the absence of appropriate therapeutic management. Complete surgical resection of the parasite at an early stage of infection provides favourable prospects for cure, but, due to a long clinical latency, many cases are diagnosed at an advanced stage, so that partial liver resection can be performed in only 35% of patients. Benzimidazole (BZM) treatment is given in inoperable cases but these compounds are only parasitostatic, and lifelong therapy is required. During the past 20 years some centres have considered liver transplantation (LT) for the treatment of incurable AE.

Methods

Our review summarizes the results of this experience based on a series of 47 European patients who received transplants between 1985 and 2002, tries to specify the real place of LT for AE, and underlines the measures that could be undertaken in the future to improve the results.

Results

Five-year survival was 71%. Five-year survival without recurrence was 58%. Major technical difficulties related either to previous laparotomies or to the loco-regional involvement were observed. The nine early deaths concerned AE patients with a long past-history of symptomatic AE (iterative cholangitis, secondary biliary cirrhosis). Five late deaths were directly related to ongoing AE, located in the brain in three cases, a very rare AE location that was not investigated before LT in these patients.

Conclusions

In general, the pre-LT screening for distant AE metastases appeared insufficient in this series. Heavy immunosuppressive schemes, absence or delayed re-introduction of BZM after LT have clearly played a role in this unfavourable course. This unique experience indicates that, despite major technical difficulties, LT for incurable AE is feasible and could be discussed in very symptomatic cases. Before LT, interventional radiology should be preferred to repeated laparotomies. Pre-LT and post-LT BZM treatment is mandatory. A careful evaluation of possible distant metastases should be done before the decision for LT is made. After LT, the possibility of an ongoing AE must be permanently kept in mind. This could be reduced by lightening the immunosuppressants, carefully following the specific circulating antibodies, and applying a systematic radiological evaluation, not only to the graft but also to the lungs and the brain.
Literatur
1.
Zurück zum Zitat Bresson-Hadni S, Vuitton DA (2001) Echinococcoses. Rev Prat 51:2091–2098PubMed Bresson-Hadni S, Vuitton DA (2001) Echinococcoses. Rev Prat 51:2091–2098PubMed
2.
Zurück zum Zitat Bresson-Hadni S, Vuitton DA, Bartholomot B, et al (2000) A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern France. Eur J Gastroenterol Hepatol 12:327–336PubMed Bresson-Hadni S, Vuitton DA, Bartholomot B, et al (2000) A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern France. Eur J Gastroenterol Hepatol 12:327–336PubMed
3.
Zurück zum Zitat Chapuis Y, Houssin D, Brouzes S, et al (1987) Hepatic transplantation in alveolar echinococcosis. 3 attempts. Chirurgie 113:634–640PubMed Chapuis Y, Houssin D, Brouzes S, et al (1987) Hepatic transplantation in alveolar echinococcosis. 3 attempts. Chirurgie 113:634–640PubMed
4.
Zurück zum Zitat Mboti B, Van de Stadt J, Carlier Y, et al (1996) Long-term disease-free survival after liver transplantation for alveolar echinococcosis. Acta Chir Belg 96:229–232PubMed Mboti B, Van de Stadt J, Carlier Y, et al (1996) Long-term disease-free survival after liver transplantation for alveolar echinococcosis. Acta Chir Belg 96:229–232PubMed
5.
Zurück zum Zitat Bresson-Hadni S, Franza A, Miguet JP, et al (1991) Orthotopic liver transplantation for incurable alveolar echinococcosis of the liver: report of 17 cases. Hepatology 13:1061–1070PubMed Bresson-Hadni S, Franza A, Miguet JP, et al (1991) Orthotopic liver transplantation for incurable alveolar echinococcosis of the liver: report of 17 cases. Hepatology 13:1061–1070PubMed
6.
Zurück zum Zitat Ammann RW, Ilitsch N, Marincek B, et al (1994) Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Hepatology 19:735–742PubMed Ammann RW, Ilitsch N, Marincek B, et al (1994) Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Hepatology 19:735–742PubMed
7.
Zurück zum Zitat Koch S, Bresson-Hadni S, Miguet JP, et al (2003) Experience of liver transplantation for incurable alveolar echinococcosis: a 45 case European collaborative report. Transplantation 75:856–863PubMed Koch S, Bresson-Hadni S, Miguet JP, et al (2003) Experience of liver transplantation for incurable alveolar echinococcosis: a 45 case European collaborative report. Transplantation 75:856–863PubMed
8.
Zurück zum Zitat Bresson-Hadni S, Laplante JJ, Lenys D, et al (1994) Seroepidemiological screening of E. multilocularis infection in 7,884 subjects of a European endemic area of alveolar echinococcosis. Am J Trop Med Hyg 51:837–846PubMed Bresson-Hadni S, Laplante JJ, Lenys D, et al (1994) Seroepidemiological screening of E. multilocularis infection in 7,884 subjects of a European endemic area of alveolar echinococcosis. Am J Trop Med Hyg 51:837–846PubMed
9.
Zurück zum Zitat Gillet M, Miguet JP, Mantion G, et al (1988) Orthotopic liver transplantation in alveolar echinococcosis of the liver: analysis of a series of six patients. Transplant Proc 20:573–576 Gillet M, Miguet JP, Mantion G, et al (1988) Orthotopic liver transplantation in alveolar echinococcosis of the liver: analysis of a series of six patients. Transplant Proc 20:573–576
10.
Zurück zum Zitat Slim K, Chipponi J, Pezet D, et al (1996) Récidive d'une échinococcose alvéolaire après transplantation hépatique. Lyon Chir 92:301–303 Slim K, Chipponi J, Pezet D, et al (1996) Récidive d'une échinococcose alvéolaire après transplantation hépatique. Lyon Chir 92:301–303
11.
Zurück zum Zitat Bresson-Hadni S, Koch S, Beurton I, et al (1999) Primary disease recurrence after liver transplantation for alveolar echinococcosis: long-term evaluation in 15 patients. Hepatology 30:857–864PubMed Bresson-Hadni S, Koch S, Beurton I, et al (1999) Primary disease recurrence after liver transplantation for alveolar echinococcosis: long-term evaluation in 15 patients. Hepatology 30:857–864PubMed
12.
Zurück zum Zitat Gottstein B, Schantz PM, Wilson JF (1985) Serological screening of Echinococcus multilocularis infections with ELISA. Lancet i:1097–1098 Gottstein B, Schantz PM, Wilson JF (1985) Serological screening of Echinococcus multilocularis infections with ELISA. Lancet i:1097–1098
13.
Zurück zum Zitat Gottstein B, Tschudi K, Eckert J, et al (1989) Em2 Elisa for the follow-up of alveolar echinococcosis after complete surgical resection of liver lesions. Trans R Soc Trop Med Hyg 83:389–393PubMed Gottstein B, Tschudi K, Eckert J, et al (1989) Em2 Elisa for the follow-up of alveolar echinococcosis after complete surgical resection of liver lesions. Trans R Soc Trop Med Hyg 83:389–393PubMed
14.
Zurück zum Zitat Bresson-Hadni S, Miguet JP, Lenys D, et al (1992) Recurrence of alveolar echinococcosis in the liver graft after liver transplantation. Hepatology 16:279–280PubMed Bresson-Hadni S, Miguet JP, Lenys D, et al (1992) Recurrence of alveolar echinococcosis in the liver graft after liver transplantation. Hepatology 16:279–280PubMed
15.
Zurück zum Zitat Liance M, Bresson-Hadni S, Vuitton DA, et al (1992) Effects of cyclosporin A on the course of murine alveolar echinococcosis and on specific cellular and humoral responses against Echinococcus multilocularis. Int J Parasitol 22:23–28CrossRefPubMed Liance M, Bresson-Hadni S, Vuitton DA, et al (1992) Effects of cyclosporin A on the course of murine alveolar echinococcosis and on specific cellular and humoral responses against Echinococcus multilocularis. Int J Parasitol 22:23–28CrossRefPubMed
16.
Zurück zum Zitat Ammann RW, Hoffmann AF, Grimm F, et al (1998) Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J Hepatol 29:994–998CrossRefPubMed Ammann RW, Hoffmann AF, Grimm F, et al (1998) Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J Hepatol 29:994–998CrossRefPubMed
17.
Zurück zum Zitat Wang X, Liu Y, Yu D (1996) Continuous therapy with albendazole for hepatic alveolar echinococcosis associated with obstructive jaundice. Clin J Intern Med 35:261–264 Wang X, Liu Y, Yu D (1996) Continuous therapy with albendazole for hepatic alveolar echinococcosis associated with obstructive jaundice. Clin J Intern Med 35:261–264
18.
Zurück zum Zitat WHO Informal Working group on Echinococcosis (1996) Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull World Health Organ 74:231–242PubMed WHO Informal Working group on Echinococcosis (1996) Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull World Health Organ 74:231–242PubMed
Metadaten
Titel
Indications and results of liver transplantation for Echinococcus alveolar infection: an overview
verfasst von
Solange Bresson-Hadni
Stéphane Koch
Jean-Philippe Miguet
Michel Gillet
Georges-André Mantion
Bruno Heyd
Dominique-Angèle Vuitton
a European group of clinicians
Publikationsdatum
01.09.2003
Verlag
Springer-Verlag
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 4/2003
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-003-0394-2

Weitere Artikel der Ausgabe 4/2003

Langenbeck's Archives of Surgery 4/2003 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.